Loading
Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
46 trials on record are attached to one of the types below rather than to Sarcomas (soft tissue, bone, GIST) itself. They are grouped by the type that holds them, so someone still working out which type they have can see the whole field from here.
Patients with advanced synovial sarcoma, a rare cancer of young adults with few effective drugs, now have an approved cell therapy that produces responses lasting about a year in a substantial minority, if their tissue type and tumour antigen match. It proves that engineered T cells can work against a solid tumour when a good target is present, which had been elusive. It is not a cure for most, requires specialised centres, and only a minority of patients are eligible.
This trial validated the radioenhancer mode of action and supported the 2019 European CE mark for NBTXR3 (Hensify) in soft-tissue sarcoma. Whether more pathological complete responses translate into fewer recurrences or longer survival was not shown here; the 2022 follow-up paper reported more R0 resections and no harm to quality of life.
Interval-compressed VDC/IE is the standard first-line chemotherapy for localised Ewing sarcoma in North America; Euro Ewing 2012 later adopted it in Europe.
Query for this cancer: (TITLE:"Sarcomas" OR ABSTRACT:"Sarcomas" OR TITLE:"soft tissue, bone, GIST" OR ABSTRACT:"soft tissue, bone, GIST" OR TITLE:"Soft Tissue Sarcoma" OR ABSTRACT:"Soft Tissue Sarcoma") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Sarcomas (soft tissue, bone, GIST), not a curated reading list.